Mitsubishi Tanabe Pharma America (MTPA) has launched a new database that locates healthcare providers, area infusion treatment centers, and in-home infusion services, with the goal of providing a one-stop convenient resource for amyotrophic lateral sclerosis (ALS) patients and caregivers. The nationwide directory is available within the ALS…

In observance of ALS Awareness Month, the ALS Therapy Development Institute (ALS TDI) has launched a campaign aimed at sparking more discussion about the progressive neurological disease. A leading non-profit drug discovery center focused solely on amyotrophic lateral sclerosis (ALS), the institute hopes to build on the awareness-promoting…

NPT520-34, an investigational small molecule for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is being tested on healthy individuals in a new Phase 1 clinical trial, its developer Neuropore Therapies has announced. Brain inflammation is a common feature among many neurodegenerative disorders, including Parkinson’s,…

Reldesemtiv (formerly known as CK-2127107) reduces lung function decline and overall disease progression, without significant adverse events, in people with amyotrophic lateral sclerosis (ALS), a Phase 2 trial shows. The study, however, did not meet its primary endpoint. The new findings from the…

A vitamin D activator molecule known as CYP27B1 is a biomarker of muscle alterations in patients with amytrophic lateral sclerosis (ALS) and may be a marker of clinical progression of the disease, according to new research. The findings, “The Vitamin D Activator, CYP27B1, is a Novel…

Radicava (edaravone) may prevent functional deterioration in amyotrophic lateral sclerosis (ALS) patients, results from a literature review suggest. Findings from the review, “Safety and Efficacy of Edaravone in Delaying Functional Decline in Amyotrophic Lateral Sclerosis: A Meta-Analysis,” were presented in a poster session at the…

The ALS Association has launched a financial aid program, called The Jane Calmes ALS Scholarship Fund, to help students whose lives are affected by amyotrophic lateral sclerosis (ALS) pursue a college degree or vocational certificate. The scholarship program will award $5,000 a year to at least 30 students whose…

Masitinib, the lead experimental medicine being developed by AB Science, can modulate the activity of different cell types known to be involved in inflammation and nerve degeneration in amyotrophic lateral sclerosis (ALS), according to results from a preclinical study. The findings were discussed in a presentation, titled “Post-paralysis treatment with…

Mesenchymal stem cells (MSCs) taken from the bone marrow of patients with amyotrophic lateral sclerosis (ALS) show an ability to control inflammation much like that seen in healthy people, but they respond differently and can be influenced by nearby pro-inflammatory molecules called cytokines, a…

A specific type of genetic alteration — known as epigenetic changes — observed in patients with amyotrophic lateral sclerosis (ALS) may lead to novel treatments and diagnostic tools, according to a review study. The study, “Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications…